Docket Management
Docket: 00N-1256 - Over-the-Counter Products
Comment Number: EC -75

Accepted - Volume 6

Comment Record
Commentor Mr. John Greene Date/Time 2000-06-29 10:30:48
Organization Mr. John Greene
Category Health Professional

Comments for FDA General
Questions
1. General Comments Since Congress can't control their appetite for money from the pharmaceutical lobby, it is incumbent on the FDA to act as the last resort to counter the industry's lobby on behalf of consumers. Current rules that allow pharmaceutical companies to halt generics in the marketplace through payoffs to generic patent seekers, thereby effectively extending their patent control and creating substantial variation in pricing structures, makes rule making in favor of OTC essential. The rule making body should cast a wary eye on the industry objections to OTC and make their decision based on current scientific and medical practice. Our layered approach to health care has added additional cost and time burdens on consumers that is unnecessary. Our policies are often fashioned as all or nothing. We have to create policies that are founded on reasonable assumptions leading to reasonable conclusions. I wish you well in your deliberations. Best Regards, John Greene.




EC -75